Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Person

George Yancopoulos

Tracked across 4 events · 33 articles · First seen May 19, 2025 · Last active May 28, 2026

Sentiment
2
Attention
4
Events
4
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 10
Tech
Impact: George Yancopoulos is the co-Founder, Board co-Chair, President, and Chief Scientific Officer of Regeneron Pharmaceuticals, and the Innovator Award is named in his honor, reflecting his commitment to STEM.
May 15, 2026 · 10 articles
4 0
Business
Impact: George Yancopoulos, co-Chair, President, and Chief Scientific Officer at Regeneron Pharmaceuticals, highlighted the significance of Dupixent's approval as a new standard of care for young children with chronic spontaneous urticaria.
Apr 13, 2026 · 8 articles
4 0
Business
Impact: George Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron Pharmaceuticals, emphasized the significance of Dupixent's approvals and its role in treating type 2 inflammatory diseases.
Feb 24, 2026 · 8 articles
4 0
Tech
Apr 23, 2026 · 7 articles
Regeneron Pharmaceuticals George Yancopoulos
Regeneron Pharmaceuticals George Yancopoulos
ERGEN INTELLIGENCE
Track George Yancopoulos live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.